UroGen Pharma Ltd (URGN) gains 1.79% for July 21

Equities Staff  |

UroGen Pharma Ltd (NASDAQ: URGN) shares gained 1.79%, or $0.28 per share, to close Wednesday at $15.95. After opening the day at $15.75, shares of UroGen Pharma fluctuated between $16.00 and $15.41. 151,364 shares traded hands a decrease from their 30 day average of 176,502. Wednesday's activity brought UroGen Pharma’s market cap to $355,664,632.

UroGen Pharma is headquartered in 9 Hataasiya St, Raanana..

About UroGen Pharma Ltd

Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Visit UroGen Pharma Ltd’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on UroGen Pharma Ltd and to follow the company’s latest updates, you can visit the company’s profile page here: UroGen Pharma Ltd’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content